Compass Therapeutics presents data on combination of CTX-009, CTX-471

Compass Therapeutics presents a poster on the combination of its bispecific antibody, CTX-009, and its agonistic anti-CD137 antibody, CTX-471, on anti-tumor activity in preclinical models at the 2024 American Association for Cancer Research Annual Meeting taking place at the San Diego Convention Center in San Diego, California on April 9. Data highlights from the poster presentation include: The combination of mCTX-009 and mCTX-471 demonstrated superior efficacy in both Checkpoint Inhibitor-sensitive and CPI-refractory models with markedly enhanced anti-tumor activity compared with either monotherapy. Following mCTX-009 and mCTX-471 combination treatment, superior efficacy was observed in MHC Class I negative tumors. Deletion of B2m produced MHC-I null phenotypes in two colorectal cancer cell lines. Tumor elimination was in part mediated by NK cells. These preclinical data suggest that the combination of CTX-009 and CTX-471 could re-establish anti-tumor immunity in patients whose tumors have either downregulated or lost MHC-I expression by way of NK-cell mediated tumor cell killing.